We evaluate and, when appropriate, enter into collaborations to expand the Company’s capabilities and product offerings into a range of diseases and potentially to more broadly accelerate the development and commercialization of ddRNAi therapeutics.

Therapeutic product partnering/out-licensing to pharmaceutical partners;

  • Benitec utilizes its in-house research and development resources to discover, evaluate (in preclinical and clinical studies), a range of novel ddRNAi therapeutics. The company is currently focused on two therapeutic areas – orphan indications associated with rare genetic mutations and infectious disease.
  • Benitec may seek to partner these therapeutic programs with leading pharmaceutical partners in the relevant disease areas as they reach key pre-clinical or clinical development milestones.

R&D collaborations and with pharmaceutical partners and specialized biotechs;

  • Benitec has unique expertise in developing ddRNAi therapeutics utilizing a range of viral vectors, including novel viral vectors for ocular disease, as well as evaluating non-viral delivery platforms. This expertise combined with internal capabilities for process development and small-scale manufacturing is a powerful drug discovery/ development platform.
  • Benitec is therefore ideally placed to become the partner of choice for pharmaceutical companies looking to enter the field of non-viral and viral vector-based gene therapy and gene silencing therapeutics as a differentiated approach to disease targets. Such partnerships may include de novo discovery and development designed to silence (and replace if required) the partner’s chosen protein target(s) within a single therapeutic to provide; a) more effective drug targeting, b) ‘in-situ’ therapeutic expression, and c) potent ‘single administration’ multi-target therapies.

For more information on business development or partnering opportunities, please contact Dr. Jerel Banks, Executive Chairman and CEO at

Stay updated today

Keep up with programs, reports, announcements and events.

Sign Up